MED Alliance International, a division of MED Alliance Group, LLC, is excited to partner with IMBiotechnologies Ltd (IMB), the manufacturer of Ekobi™ Embolization Microspheres (Ekobi) used in therapeutic embolization procedures. Ekobi is the only embolic agent that is biodegradable and detectable by ultrasound.
IMB, a Canadian-based company, is partnering with MED Alliance to provide logistical and operational support to provide Ekobi to U.S. and Canadian clinical customers. IMB’s mission is to create and commercialize innovative products that treat human disease and improve quality of life. Ekobi is approved in Canada for the treatment of hypervascularized tumors, uterine fibroids, and enlarged prostates due to benign prostatic hyperplasia. Ekobi is cleared for the treatment of unresectable/inoperable hypervascularized tumors in the U.S.
“MED Alliance International’s dedication to ISO certification and our strong relationships with U.S. hospitals can benefit companies like IMB who are working toward expanding their market share in the U.S. and Canada,” said MED Alliance Vice President of Operations and Finance Lindsey Allende. “We take the guesswork out of the equation, eliminate barriers and provide channels to help our partners grow.”
“MED Alliance provides key logistical support in supplying Ekobi to IMB’s customers in a timely manner. This partnership allows IMB to meet market demand for this innovative product. Ekobi delivers a therapeutic benefit then biodegrades; it is not a permanent implant,” said IMB CEO Michael Stewart. “Ekobi is directly imaged using standard ultrasound, providing a distinct advantage in embolization procedures.”
Learn more about Ekobi Microspheres.
MED Alliance International is an ISO 13485 certified medical device distributor offering domestic and foreign medical device manufacturers specialized logistical and operational solutions. We are dedicated to partnering with manufacturers of high quality, cost-effective and innovative medical devices that improve patient care. We are delighted to add IMBiotechnologies to our portfolio of manufacturing partners.
Embolotherapy works by reducing or eliminating the blood supply to target tissues. The procedure is performed by injecting embolic agents through a catheter into the blood vessels that feed the target tissue. By selectively blocking the tissue’s blood supply, the target tissue is either destroyed or devitalized, resulting in therapeutic benefit.
About IMBiotechnologies Ltd
IMBiotechnologies Ltd. is a privately held Canadian medical device company located in Edmonton, Alberta, focused on the commercialization of medical products in the area of embolotherapy.
For more information, email Director of Marketing and Business Development Kelly Mottet or call (780) 233-4294.
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.